Skip to Main Content
Try STAT+ TODAY
Trending:
The Obesity Revolution
Health
STAT+
Biotech
Subscribe Now To access exclusive content, subscribe to STAT+
View Latest View the latest STAT+ stories
Biotech
STAT+

Pharma’s latest Alzheimer’s failure comes with a particular sting

  • Damian Garde

By Damian Garde Feb. 13, 2018

Reprints
Evan Vucci/AP

A year ago, when Merck’s (MRK) latest treatment for Alzheimer’s disease came up a dud, the company saw a silver lining. By targeting patients with early forms of the disease, yet to show major symptoms, researchers saw a winning pathway for the drug, which looked like it was hitting its molecular targets.

They were wrong.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

About the Author Reprints

Damian Garde

Damian Garde

National Biotech Reporter

Damian Garde covers biotech, is a co-writer of The Readout newsletter, and a co-host of "The Readout LOUD" podcast.

Tags

Watch: P-value, an important measurement in clinical trials, explained
Watch: P-value, an important measurement in clinical trials, explained
‘I’m terrified’: Patients scramble for treatment after 13 ketamine…
‘I’m terrified’: Patients scramble for treatment after 13 ketamine clinics shut down
Vote now in STAT Madness 2023
Vote now in STAT Madness 2023
Top FDA official: Agency needs to start using accelerated…
Top FDA official: Agency needs to start using accelerated approval for gene therapies
Higher cancer rates found in military pilots, ground crews
Higher cancer rates found in military pilots, ground crews
Pharmalittle: Manufacturers say bird flu shots for humans can…
Pharmalittle: Manufacturers say bird flu shots for humans can be made quickly; obesity guidelines for children…

Recommended Stories